New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
16:11 EDTQDELQuidel reports Q4 EPS 37c, may not compare to consensus 17c
Reports Q4 revenue $53.9M, consensus $53.26M. The company said its increase in revenue was driven by growth of infectious disease products in the quarter, due to the onset of an early and severe influenza and respiratory disease season. Quidel reported Q4 GAAP EPS of 26c, which may compare to consensus.
News For QDEL From The Last 14 Days
Check below for free stories on QDEL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
09:15 EDTQDELQuidel receives FDA clearance for AmpliVue GAS Assay
Subscribe for More Information
July 25, 2014
14:51 EDTQDELQuidel management to meet with Piper Jaffray
Meeting to be held in St. Louis on July 31 hosted by Piper Jaffray.
July 23, 2014
10:02 EDTQDELOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:14 EDTQDELQuidel upgraded to Neutral from Underperform at Wedbush
Subscribe for More Information
July 22, 2014
07:08 EDTQDELLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use